The true extent of the risks became apparent on April 2, 2024, when Verve announced the Heart-1 trial’s suspension due to issues with the drug’s delivery system. The revelation triggered a 34.9% plunge in Verve’s stock price, as detailed in the lawsuit.
Legal Actions and Representation
Oldroyd’s lawsuit accuses Verve Therapeutics and its executives of violating the Exchange Act and seeks compensation for the financial losses suffered by investors. The Rosen Law Firm PA’s Joshua Baker represents Oldroyd, while Verve has yet to comment on the lawsuit or provide information about its legal counsel.
As the case unfolds, the biotech industry and investors alike will be watching closely to see how Verve Therapeutics navigates these serious allegations and the impact on its ongoing research and market performance.
